JP2025502098A5 - - Google Patents

Info

Publication number
JP2025502098A5
JP2025502098A5 JP2024541046A JP2024541046A JP2025502098A5 JP 2025502098 A5 JP2025502098 A5 JP 2025502098A5 JP 2024541046 A JP2024541046 A JP 2024541046A JP 2024541046 A JP2024541046 A JP 2024541046A JP 2025502098 A5 JP2025502098 A5 JP 2025502098A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
approximately
patient
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024541046A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025502098A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2023/050172 external-priority patent/WO2023131922A1/en
Publication of JP2025502098A publication Critical patent/JP2025502098A/ja
Publication of JP2025502098A5 publication Critical patent/JP2025502098A5/ja
Pending legal-status Critical Current

Links

JP2024541046A 2022-01-10 2023-01-09 うつ病の治療のための組成物及び方法 Pending JP2025502098A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263298067P 2022-01-10 2022-01-10
US63/298,067 2022-01-10
PCT/IB2023/050172 WO2023131922A1 (en) 2022-01-10 2023-01-09 Compositions and methods for the treatment of depression

Publications (2)

Publication Number Publication Date
JP2025502098A JP2025502098A (ja) 2025-01-24
JP2025502098A5 true JP2025502098A5 (https=) 2026-01-19

Family

ID=84981591

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024541046A Pending JP2025502098A (ja) 2022-01-10 2023-01-09 うつ病の治療のための組成物及び方法

Country Status (6)

Country Link
US (1) US20250090482A1 (https=)
EP (1) EP4463144A1 (https=)
JP (1) JP2025502098A (https=)
CN (1) CN118524832A (https=)
CA (1) CA3247226A1 (https=)
WO (1) WO2023131922A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4687860A1 (en) * 2023-03-24 2026-02-11 Janssen Pharmaceutica NV Esketamine for use in the treatment of depression

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19723133A1 (de) 1997-06-03 1998-12-10 Caideil M P Teoranta Tourmakea Austragvorrichtung für Medien
JP2022548233A (ja) * 2019-09-13 2022-11-17 ヤンセン ファーマシューティカルズ，インコーポレーテッド エスケタミンの鼻腔内投与

Similar Documents

Publication Publication Date Title
Huang et al. New treatment strategies of depression: based on mechanisms related to neuroplasticity
Lee et al. The effect of early neuromuscular electrical stimulation therapy in acute/subacute ischemic stroke patients with dysphagia
JP2020180141A5 (https=)
Block et al. Emerging antidepressants to treat major depressive disorder
RU2006140964A (ru) Применение флибансерина для лечения предменструальных и иных сексуальных расстройств у женщин
Akpinar et al. Efficacy of transcranial magnetic stimulation in treatment-resistant depression
CN107823195A (zh) R‑氯胺酮在抑郁症急性期治疗中的应用
JP2025502098A5 (https=)
JP2022552808A (ja) Ｇａｂａ－ａ受容体陽性アロステリック調節因子と、ｎｍｄａ拮抗薬、ｎｍｄａ陰性アロステリック調節因子、またはｎｍｄａ部分作動薬との組み合わせ
JP2022546456A5 (https=)
RU2017107033A (ru) Способы лечения депрессии с применением модуляторов nmda
Stansbury et al. The use of lobelia in the treatment of asthma and respiratory illness
JP2025503649A5 (https=)
US20240018231A1 (en) Intranasal immunotherapt for the treatment of alzheimer's disease
RU2024122072A (ru) Композиции и способы лечения депрессии
JP2025503646A5 (https=)
Hagiu Vasodilators, enhancers of prevention through exercise of COVID-19
Lee et al. Studies on a novel regimen for management of orofacial pain and morphine tolerance
Gersten et al. Transcranial direct current stimulation (tDCS) for major depressive disorder
MX2024003547A (es) Metodos terapeuticos que usan hidrobromuro de bupropion
Novák et al. Repetitive transcranial magnetic stimulation (rTMS) in the treatment of bipolar depression
Benussi et al. Effects of cerebello-spinal stimulation in neurodegenerative ataxia on motor and cognitive outcomes: a randomized, double-blind, sham-controlled trial followed by an open-label phase
Brainch et al. D-Cycloserine: A Novel Antidepressant to Be Explored?
GUO Therapeutic effect of metoprolol tartrate on UAP and its influence on levels of blood lipids and inflam‐matory factors
Zwanzger et al. Repetitive transcranial magnetic stimulation in major depression—The impact of stimulation intensity on therapeutic efficacy